FindTrial
Sign In

Treatment of Sickle cell Anemia by Herbal medicines

A Clinico-Pathological study of Sickle Cell Anemia WSR to Sannipatika Pandu and Management by Poly Herbal Formulation with Standard Care - MANAGEMENT OF SCA WITH PHF WITH STANDARD CARE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076415
Enrollment
100
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D570- Hb-SS disease with crisis Health Condition 2: D570- Hb-SS disease with crisis

Interventions

None listed

Sponsors

Self
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Having Clinical Sign and Symptoms of SCD. (as per VAS score) and Vaso-occlusive events 1-10 in past 12 months

Exclusion criteria

Exclusion criteria: Heterozygous sickle cell disease(HbAS)

Design outcomes

Primary

MeasureTime frame
Poly herbal formulation(Trial drug) is effective in treating Sickle Cell Anaemia Stabilisation.Timepoint: One year—

Secondary

MeasureTime frame
Poly herbal formulation is more effective than Hydroxyurea(Control drug) for Prophylactic management of Sickle Cell Anaemia .Timepoint: Poly herbal formulation is more effective than Hydroxyurea(Control drug) for Prophylactic management of Sickle Cell Anaemia .—

Countries

India

Contacts

Public ContactDr Harish Chandra Giri

Sri Sri College of ayurvedic science and research hospital

deansscasrh@srisriuniversity.edu.in9777868699

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026